Evaluation of Ipatasertib Interactions with Itraconazole and Coproporphyrin I and III in a Single Drug Interaction Study in Healthy Subjects

Ipatasertib is a pan-AKT inhibitor in development for the treatment of cancer. Ipatasertib was metabolized by CYP3A4 to its major metabolite, M1 (G-037720), and was a P-gp substrate and OATP1B1/1B3 inhibitor in vitro. A phase I drug-drug interaction (DDI) study ( = 15) was conducted in healthy subje...

Celý popis

Podrobná bibliografie

Vydáno v:	The Journal of pharmacology and experimental therapeutics Ročník 378; číslo 2; s. 87
Hlavní autoři:	Sane, Rucha S, Cheung, Kit Wun Kathy, Cho, Eunpi, Liederer, Bianca M, Hanover, Justin, Malhi, Vikram, Plise, Emile, Wong, Susan, Musib, Luna
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States 01.08.2021
Témata:	Adult Coproporphyrins - metabolism Cytochrome P-450 CYP3A - metabolism Drug Interactions Female Healthy Volunteers Humans Itraconazole - pharmacology Male Middle Aged Piperazines Pyrimidines - pharmacokinetics Pyrimidines - pharmacology Young Adult
ISSN:	1521-0103, 1521-0103
On-line přístup:	Zjistit podrobnosti o přístupu
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!